CTLA4 and ovarian cancer: On the other hand, Wistuba and colleagues, among others, have shown the clinical relevance of bloodborne Vδ2 and not Vδ1 in response to anti-CTLA4 in patients with melanoma53, while in ovarian cancer, Foord and colleagues reported no apparent role in antitumor activity for Vδ1 T cells, which showed an exhausted-like phenotype and did not correlate with clinical benefit54.